Literature DB >> 14571073

Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method.

M A de Rie1, D N H Enomoto, H J C de Vries, J D Bos.   

Abstract

PURPOSE: To evaluate the efficacy of medium-dose UVA1 phototherapy in patients with localized scleroderma.
METHOD: A controlled pilot study with medium-dose UVA1 (48 J/cm2) was performed. The results were evaluated by means of a skin score and two objective methods for quantifying sclerosis (cutometer and fast Fourier transform method). Patients were treated 4 times a week for 5 weeks. The follow-up period was 12 weeks.
RESULTS: All patients responded to therapy. Skin score and cutometer results showed improvement of skin elasticity of treated skin compared to control skin. Fast Fourier transform measurements showed no change in bundle orientation ratio and spacing.
CONCLUSION: We concluded that treatment for 12 weeks 4 times a week with medium-dose UVA1 may be a beneficial therapy and a well-tolerated treatment modality for localized scleroderma (morphea). After 12 weeks, improvement of skin sclerosis can be detected by skin score and cutometer measurements but not by the fast Fourier transform method. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2003        PMID: 14571073     DOI: 10.1159/000073093

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  12 in total

1.  Low-dose Ultraviolet A1 Phototherapy for Treating Pityriasis Rosea.

Authors:  Sang Hee Lim; Sang Min Kim; Byung Ho Oh; Jong Hyun Ko; Yang Won Lee; Yong Beom Choe; Kyu Joong Ahn
Journal:  Ann Dermatol       Date:  2009-08-31       Impact factor: 1.444

2.  Efficacy of ultraviolet A1 phototherapy in recalcitrant skin diseases.

Authors:  Kee Suck Suh; Jin Seuk Kang; Jae Woo Baek; Tae Kwon Kim; Jin Woo Lee; Young Seung Jeon; Min Soo Jang; Sang Tae Kim
Journal:  Ann Dermatol       Date:  2010-02-28       Impact factor: 1.444

Review 3.  [Morphea or localized scleroderma and extragenital lichen sclerosus].

Authors:  P Moinzadeh; A Kreuter; T Krieg; N Hunzelmann
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

4.  UVA1 a promising approach for scleroderma.

Authors:  Uma Keyal; Anil Kumar Bhatta; Xiu Li Wang
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

Review 5.  Pediatric scleroderma: systemic or localized forms.

Authors:  Kathryn S Torok
Journal:  Pediatr Clin North Am       Date:  2012-04-06       Impact factor: 3.278

6.  Fractional carbon dioxide laser versus low-dose UVA-1 phototherapy for treatment of localized scleroderma: a clinical and immunohistochemical randomized controlled study.

Authors:  S M Shalaby; M Bosseila; M M Fawzy; D M Abdel Halim; S S Sayed; R S H M Allam
Journal:  Lasers Med Sci       Date:  2016-08-10       Impact factor: 3.161

Review 7.  UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review.

Authors:  Frank Breuckmann; Thilo Gambichler; Peter Altmeyer; Alexander Kreuter
Journal:  BMC Dermatol       Date:  2004-09-20

Review 8.  Morphea and Eosinophilic Fasciitis: An Update.

Authors:  Jorre S Mertens; Marieke M B Seyger; Rogier M Thurlings; Timothy R D J Radstake; Elke M G J de Jong
Journal:  Am J Clin Dermatol       Date:  2017-08       Impact factor: 7.403

Review 9.  Morphea - selected local treatment methods and their effectiveness.

Authors:  Joanna Narbutt; Agnieszka Hołdrowicz; Aleksandra Lesiak
Journal:  Reumatologia       Date:  2017-12-30

Review 10.  Phototherapy in Scleroderma.

Authors:  John Hassani; Steven R Feldman
Journal:  Dermatol Ther (Heidelb)       Date:  2016-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.